Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Clinical and Genetic Investigation of Pituitary and Hypothalamic Tumors and Related Disorders

There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central…

PanhypopituitarismGigantism/AcromegalyProlactinoma+1 more

Estimated

~$10 – $675

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT00001595

Phase 3

A Phase 3 Randomized 3-arm Trial (Double-blind Debio 4126, Placebo Control, and Open-label Debio 4126), to Assess the Efficacy and Safety of Debio 4126, a 12-week Octreotide Formulation, in Patients With Acromegaly Previously Treated With Somatostatin Analogs

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limi…

Acromegaly

Estimated

~$10 – $7,500

Debiopharm International SANCT06930625

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly

Acromegaly

Estimated

~$10 – $8,750

Marea TherapeuticsNCT07641179

Phase 1

First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Acromegaly

Estimated

~$10 – $8,750

Marea TherapeuticsNCT07195175

Phase 2

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination With Somatostatin Analogs in Adult Participants With Acromegaly

The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF…

Acromegaly

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07037420